Study protocol and preliminary results from a mono-centric cohort within a trial testing stereotactic body radiotherapy and abiraterone (ARTO-NCT03449719).

ABSTRACT:

Background

ARTO trial was designed to evaluate the difference in terms of outcomes between patients affected by oligo metastatic castrate resistant prostate cancer (mCRPC) treated with Abiraterone acetate and randomized to receive or not SBRT on all sites of disease. Here, we present a preliminary analysis conducted on patients enrolled at promoting institution.

Objective

To present a preliminary overview about population features, clinical outcomes, adverse events, quality of life and explorative translational research.

Design, setting, and participants

ARTO (NCT03449719) is a phase II trial including patients affected by oligo mCRPC, randomized to receive standard of care (GnRH agonist or antagonist plus abiraterone acetate 1000 mg and oral prednisone 10 mg daily) w

SUBMITTER: Francolini G 

PROVIDER: S-EPMC9349091 | biostudies-literature | 2022 Aug

REPOSITORIES: biostudies-literature